Healthcare Economist Unbiased Analysis of Today’s Healthcare Issues
- Weekend Readingby Jason Shafrin on June 28, 2025 at 1:03 am
Renaming schizophrenia: why, how, and what next? COVID-19 winners and losers. Labor market (not supply chain) caused COVID-19 inflation? Medicare Advantage dental benefits. NC eliminating parking minimums.
- 20% of the economy will be spent on health care by 2033by Jason Shafrin on June 27, 2025 at 1:23 am
CMS’s Office of the Actuary predicts that national healthcare expenditures (NHE) will increase from 17.6% of GDP in 2023 to 20.3% of GDP by 2033. The Keehan et al. (2025) paper provides more details: National health expenditures are projected to have grown 8.2 percent in 2024 and to increase 7.1 percent in 2025, reflecting continued…
- Impact of financial incentives on the value of the marginal drugby Jason Shafrin on June 26, 2025 at 1:49 am
From an interesting review paper in the Journal of Economic Perspectives by Craig Garthwaite: Although research and development investments clearly respond to market opportunities, the exact benefits created by these incremental investments remain unclear. This is largely because the exact marginal products developed in response to these incentives are elusive to identify. Certainly, the amount…
- AHIP to simplify prior authorization processby Jason Shafrin on June 25, 2025 at 3:31 am
AHIP (formerly America’s Health Insurance Plans) released a statement yesterday saying that their health plan members “announced a series of commitments to streamline, simplify and reduce prior authorization.” 48 US health plans signed off on the statement. What were AHIP’s 6 commitments? Standardizing Electronic Prior Authorization. Participating health plans will work toward implementing common, transparent submissions…
- Cost impact of BTKi selection in Medicare patients with CLLby Jason Shafrin on June 23, 2025 at 6:32 pm
That is the title of my paper out today in the Journal of Comparative Effectiveness Research written with co-authors Adam Kittai, Dipen Patel, Nadine Zawadzki, Vikram Shetty, Yazan Barqawi, and Joanna Rhodes. The abstract is below. Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and…